Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company ...
BioSpace

FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence ...

US FDA declines to approve Outlook's eye disease drug for second time in 2025

Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, ...
American Association of Individual Investors

Why Outlook Therapeutics, Inc.’s (OTLK) Stock Is Down 55.57%

As of Friday, January 02, Outlook Therapeutics, Inc.’s OTLK share price has dipped by 55.57%, which has investors questioning ...
TipRanks on MSN

The narrowing pathway for biotech securities fraud claims: Lessons from Outlook Therapeutics

Litigation Trend Analysis The December 23, 2025 decision in In re Outlook Therapeutics, Inc. Securities Litigation (D.N.J., ...
Ophthalmology Times

FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA

The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials ...

US FDA declines to approve Outlook Therapeutics' eye disease drug

Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, ...

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...

Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks

U.S. futures are trading higher with Nasdaq 100 Futures futures up as much as 1.1% in pre-market Friday. ASML (NASDAQ:ASML) are up 4.9% after Aletheia Capital double-upgraded the European-listed ...